Lung Cancer Genomic Screening Project for Individualized Medicine Molecular Testing for Resistant Tumors to Systemic Therapy

Conditions

Non-small cell lung cancer

Hiroki Izumi, Shingo Matsumoto, Shuji Murakami, SHOICHI ISHIKAWA, Shoichiro Yamamoto et al. (19 authors)

Journal of Clinical Oncology2026-05-28

10.1200/jco.2026.44.16_suppl.8626

Clinical-genomic characteristics in patients with EGFR-mutated non-small cell lung cancer harboring MET copy number gains after progression on EGFR-TKI: A report from LC-SCRUM-TRY.

Tsuyoshi Hirata, Hiroki Izumi, Shingo Matsumoto, Kazumi Nishino, Terufumi Kato et al. (20 authors)

Journal of Clinical Oncology2024-06-01

10.1200/jco.2024.42.16_suppl.8628

A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).

Hiroki Izumi, Shingo Matsumoto, Kazumi Nishino, Terufumi Kato, Satoshi Hara et al. (20 authors)

Journal of Clinical Oncology2023-06-01

10.1200/jco.2023.41.16_suppl.9097

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients aged 16 years or older 2)Patients with pathologically (histology or cytology) confirmed non-small cell lung cancer (NSCLC) 3)Patients who have received one or more drug regimens for lung cancer. Patients with treatment-naive NSCLC can be enrolled if blood sample is submitted. (Preoperative/postoperative adjuvant chemotherapy is not included in the calculation of the number of regimens. Chemoradiotherapy is included in the calculation of the number of regimens.) 4)Eastern Cooperative Oncology Group performance status (PS) of 0 or 2 5)Patients who are expected to live for at least 3 months from the date of study enrollment 6)Patients who are able to submit samples that can be used for genetic analyses. 7)Patients who consider to enroll in genotype-directed clinical trials if the target gene alterations are identified in this study 8)Patients who have provided written consent to enroll in this study

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
To characterize the clinicopathological and molecular biological features of lung cancer with genetic alterations identified in the genomic screening.	—

Countries

Japan

Contacts

Public ContactHiroki Izumi

National Cancer Center Hospital East Department of Thoracic Oncology

hiroizum@east.ncc.go.jp04-7133-1111

Outcome results